Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00262314 · ClinicalTrials.gov registry record
Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients
A clinical trial of Multiple Sclerosis, sponsored by EMD Serono.
- Completed
- Registry status
- 509
- Enrollment target
- 1
- Study location
NCT00262314: Completed study of Multiple Sclerosis, sponsored by EMD Serono.
NCT00262314 is a study of Multiple Sclerosis that has completed, run by EMD Serono. The registered enrollment target is 509 participants, below the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00262314, a study of Multiple Sclerosis, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- 509 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.
Primary Outcome
Number of patients experiencing congestive heart failure during the treatment phase of the trial
Conditions Studied
Study Locations (1)
Kentucky
- Registrat Inc - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2000-10 |
| Est. Completion | 2008-09 |
What the finished NCT00262314 record still lists
NCT00262314 is an observational study that tracks outcomes without assigning an intervention. The registered 509 participants enrollment target is mid-sized for trials with a published cap, below the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT00262314 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT00262314 about?
NCT00262314 is a clinical study titled "Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients". The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.
What is the current status of trial NCT00262314?
This trial is currently completed. The enrollment target is 509 participants. The study started on 2000-10. Estimated completion is 2008-09.
What conditions does trial NCT00262314 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
Who is sponsoring clinical trial NCT00262314?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00262314 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00262314's enrollment target sits among peer trials
509 41st of 315 higher than 275 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia